Terns Pharmaceuticals Inc (NASDAQ: TERN) is 5.08% higher on its value in year-to-date trading and has touched a low of $3.26 and a high of $10.03 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TERN stock was last observed hovering at around $6.66 in the last trading session, with the day’s gains setting it 0.16%.
Currently trading at $6.82, the stock is -18.91% and -10.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 2.40% at the moment leaves the stock 8.58% off its SMA200. TERN registered -2.43% loss for a year compared to 6-month gain of 19.44%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -6.58% loss in the last 1 month and extending the period to 3 months gives it a 12.73%, and is -12.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.53% over the week and 9.55% over the month.
Terns Pharmaceuticals Inc (TERN) has around 66 employees, a market worth around $479.92M and $0.00M in sales. Distance from 52-week low is 109.20% and -32.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-43.85%).
The EPS is expected to shrink by -0.98% this year
The shares outstanding are 64.58M, and float is at 47.91M with Short Float at 4.16%.
Terns Pharmaceuticals Inc (TERN) Insider Activity
The most recent transaction is an insider sale by Quigley Jill M., the company’s Director. SEC filings show that Quigley Jill M. sold 8,857 shares of the company’s common stock on Aug 02 ’24 at a price of $7.50 per share for a total of $66432.0. Following the sale, the insider now owns 15000.0 shares.
Terns Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 01 ’24 that Quigley Jill M. (Director) sold a total of 6,143 shares of the company’s common stock. The trade occurred on Aug 01 ’24 and was made at $7.68 per share for $47148.0. Following the transaction, the insider now directly holds 23857.0 shares of the TERN stock.
Still, SEC filings show that on Jul 16 ’24, ORBIMED ADVISORS LLC (Director) disposed off 5,188 shares at an average price of $10.00 for $51880.0. The insider now directly holds 755,635 shares of Terns Pharmaceuticals Inc (TERN).
